Your browser doesn't support javascript.
Plasma miRNA profile at COVID-19 onset predicts severity status and mortality.
Fernández-Pato, Asier; Virseda-Berdices, Ana; Resino, Salvador; Ryan, Pablo; Martínez-González, Oscar; Pérez-García, Felipe; Martin-Vicente, María; Valle-Millares, Daniel; Brochado-Kith, Oscar; Blancas, Rafael; Martínez, Amalia; Ceballos, Francisco C; Bartolome-Sánchez, Sofía; Vidal-Alcántara, Erick Joan; Alonso, David; Blanca-López, Natalia; Ramirez Martinez-Acitores, Ignacio; Martin-Pedraza, Laura; Jiménez-Sousa, María Ángeles; Fernández-Rodríguez, Amanda.
  • Fernández-Pato A; Unit of Viral Infection and Immunity, National Center for Microbiology (CNM), Health Institute Carlos III (ISCIII), Madrid, Spain.
  • Virseda-Berdices A; Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Resino S; Unit of Viral Infection and Immunity, National Center for Microbiology (CNM), Health Institute Carlos III (ISCIII), Madrid, Spain.
  • Ryan P; Unit of Viral Infection and Immunity, National Center for Microbiology (CNM), Health Institute Carlos III (ISCIII), Madrid, Spain.
  • Martínez-González O; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
  • Pérez-García F; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
  • Martin-Vicente M; Department of Infectious Diseases, Hospital Universitario Infanta Leonor, Madrid, Spain.
  • Valle-Millares D; School of Medicine, Complutense University of Madrid, Madrid, Spain.
  • Brochado-Kith O; Gregorio Marañón Health Research Institute, Madrid, Spain.
  • Blancas R; Critical Care Department, Hospital Universitario del Tajo, Aranjuez, Spain.
  • Martínez A; Clinical Microbiology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain.
  • Ceballos FC; Department of Biomedicine and Biotechnology, Faculty of Medicine, University of Alcalá de Henares, Madrid, Spain.
  • Bartolome-Sánchez S; Unit of Viral Infection and Immunity, National Center for Microbiology (CNM), Health Institute Carlos III (ISCIII), Madrid, Spain.
  • Vidal-Alcántara EJ; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
  • Alonso D; Unit of Viral Infection and Immunity, National Center for Microbiology (CNM), Health Institute Carlos III (ISCIII), Madrid, Spain.
  • Blanca-López N; Unit of Viral Infection and Immunity, National Center for Microbiology (CNM), Health Institute Carlos III (ISCIII), Madrid, Spain.
  • Ramirez Martinez-Acitores I; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
  • Martin-Pedraza L; Critical Care Department, Hospital Universitario del Tajo, Aranjuez, Spain.
  • Jiménez-Sousa MÁ; Department of Infectious Diseases, Hospital Universitario Infanta Leonor, Madrid, Spain.
  • Fernández-Rodríguez A; Unit of Viral Infection and Immunity, National Center for Microbiology (CNM), Health Institute Carlos III (ISCIII), Madrid, Spain.
Emerg Microbes Infect ; 11(1): 676-688, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1672036
ABSTRACT

BACKGROUND:

MicroRNAs (miRNAs) have a crucial role in regulating immune response against infectious diseases, showing changes early in disease onset and before the detection of the pathogen. Thus, we aimed to analyze the plasma miRNA profile at COVID-19 onset to identify miRNAs as early prognostic biomarkers of severity and survival. METHODS AND

RESULTS:

Plasma miRNome of 96 COVID-19 patients that developed asymptomatic/mild, moderate and severe disease was sequenced together with a group of healthy controls. Plasma immune-related biomarkers were also assessed. COVID-19 patients showed 200 significant differentially expressed (SDE) miRNAs concerning healthy controls, with upregulated putative targets of SARS-CoV-2, and inflammatory miRNAs. Among COVID-19 patients, 75 SDE miRNAs were observed in asymptomatic/mild compared to symptomatic patients, which were involved in platelet aggregation and cytokine pathways, among others. Moreover, 137 SDE miRNAs were identified between severe and moderate patients, where miRNAs targeting the SARS CoV-2 genome were the most strongly disrupted. Finally, we constructed a mortality predictive risk score (miRNA-MRS) with ten miRNAs. Patients with higher values had a higher risk of 90-days mortality (hazard ratio = 4.60; p-value < 0.001). Besides, the discriminant power of miRNA-MRS was significantly higher than the observed for age and gender (AUROC = 0.970 vs. 0.881; p = 0.042).

CONCLUSIONS:

SARS-CoV-2 infection deeply disturbs the plasma miRNome from an early stage of COVID-19, making miRNAs highly valuable as early predictors of severity and mortality.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: MicroRNAs / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article Affiliation country: 22221751.2022.2038021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: MicroRNAs / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article Affiliation country: 22221751.2022.2038021